← Back to Search

Imaging Techniques for Acute Myeloid Leukemia

Phase 1
Waitlist Available
Led By Dawid Schellingerhout
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with newly diagnosed AML or acute promyelocytic leukemia (APL)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at time of imaging
Awards & highlights

Study Summary

This trial is looking at using PET/MRI, 18F-FDG PET/CT, and whole body MRI to detect extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia.

Who is the study for?
This trial is for patients with newly diagnosed acute myeloid leukemia (AML) or acute promyelocytic leukemia (APL). Women who can have children must show a negative pregnancy test to participate.Check my eligibility
What is being tested?
The study tests how well PET/MRI, 18F-FDG PET/CT, and whole body MRI detect extramedullary myeloid leukemia in new AML patients. These imaging techniques may improve diagnosis of cancer outside the bone marrow.See study design
What are the potential side effects?
Since this trial focuses on diagnostic procedures rather than treatments, side effects are minimal but may include discomfort during scans and potential allergic reactions to contrast agents like Gadolinium.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been recently diagnosed with AML or APL.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at time of imaging
This trial's timeline: 3 weeks for screening, Varies for treatment, and at time of imaging for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of extramedullary myeloid leukemia (EML)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (18F-FDG PET/CT, whole body PET/MRI)Experimental Treatment7 Interventions
Patients receive gadolinium IV and undergo whole body PET/MRI comprising diffusion weighted imaging and 3D FSPGR-DE with and without fiducial markers. Patients then undergo 18F-FDG PET/CT before start treatment for acute myeloid leukemia.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Diffusion Weighted Imaging
2006
Completed Phase 2
~150
Magnetic Resonance Imaging
2017
Completed Phase 3
~1160
Fludeoxyglucose F-18
2018
Completed Phase 4
~590
Computed Tomography
2017
Completed Phase 2
~2720
Fludeoxyglucose (18F)
FDA approved
Positron Emission Tomography
2008
Completed Phase 2
~2210

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,718 Previous Clinical Trials
40,963,336 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
2,992 Previous Clinical Trials
1,792,598 Total Patients Enrolled
Dawid SchellingerhoutPrincipal InvestigatorM.D. Anderson Cancer Center
2 Previous Clinical Trials
25 Total Patients Enrolled

Media Library

Diagnostic (18F-FDG PET/CT, whole body PET/MRI) Clinical Trial Eligibility Overview. Trial Name: NCT02390635 — Phase 1
Acute Promyelocytic Leukemia Research Study Groups: Diagnostic (18F-FDG PET/CT, whole body PET/MRI)
Acute Promyelocytic Leukemia Clinical Trial 2023: Diagnostic (18F-FDG PET/CT, whole body PET/MRI) Highlights & Side Effects. Trial Name: NCT02390635 — Phase 1
Diagnostic (18F-FDG PET/CT, whole body PET/MRI) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02390635 — Phase 1
~2 spots leftby Sep 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top